Yes, CRISPR gene-editing technology has been successfully used on humans in milestone clinical trials and approved medical treatments. Regulatory bodies in the United States, the United Kingdom, and Europe have granted historic approvals for CRISPR-based therapies—such as Casgevy—to treat severe genetic blood disorders like sickle cell disease and beta thalassemia by editing human stem cells. Furthermore, advanced clinical trials and personalized experimental treatments are actively testing in-vivo and ex-vivo CRISPR applications for inherited blindness, cancers, and rare metabolic conditions.